{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:47:17Z","timestamp":1789602437015,"version":"build-2803163510"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,5,26]],"date-time":"2012-05-26T00:00:00Z","timestamp":1337990400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1007\/s12185-012-1103-0","type":"journal-article","created":{"date-parts":[[2012,5,25]],"date-time":"2012-05-25T09:45:37Z","timestamp":1337939137000},"page":"132-135","source":"Crossref","is-referenced-by-count":17,"title":["Elevation of pulmonary artery pressure as a complication of nilotinib therapy for chronic myeloid leukemia"],"prefix":"10.1007","volume":"96","author":[{"given":"Dariusz","family":"Zakrzewski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilona","family":"Seferynska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Warzocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Hryniewiecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,5,26]]},"reference":[{"key":"1103_CR1","unstructured":"TASIGNA\u00ae (nilotinib) capsules prescribing information. Novartis Pharmaceuticals Corporation, East Hanover, NJ. 2010."},{"key":"1103_CR2","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1182\/blood-2007-01-070144","volume":"110","author":"Y Will","year":"2007","unstructured":"Will Y, Dykens JA, Nadanaciva S, Hirakawa B, Jamieson J, Marroquin LD, et al. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood. 2007;110:1233\u20137.","journal-title":"Blood"},{"key":"1103_CR3","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/j.leukres.2008.03.020","volume":"32","author":"AL Ribeiro","year":"2008","unstructured":"Ribeiro AL, Marcolino MS, Bittencourt HN, Barbosa MM. An evaluation of the cardiotoxicity of imatinib mesylate. Leuk Res. 2008;32:1809\u201314.","journal-title":"Leuk Res"},{"key":"1103_CR4","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1093\/toxsci\/kfn157","volume":"106","author":"Y Will","year":"2008","unstructured":"Will Y, Dykens JA, Nadanaciva S, Hirakawa B, Jamieson J, Marroquin LD, et al. Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib and sorafenib on mitochondria function in isolated rat heart mitochondria and H9c2 cells. Toxicol Sci. 2008;106:153\u201361.","journal-title":"Toxicol Sci"},{"key":"1103_CR5","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.leukres.2010.11.001","volume":"35","author":"A Wolf","year":"2011","unstructured":"Wolf A, Couttet P, Dong M, Grenet O, Heron M, Junker U, et al. Preclinical evaluation of potential nilotinib cardiotoxicity. Leuk Res. 2011;35:631\u20137.","journal-title":"Leuk Res"},{"issue":"6","key":"1103_CR6","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.leukres.2008.09.026","volume":"33","author":"W Rasheed","year":"2009","unstructured":"Rasheed W, Flaim B, Seymour JF. Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia. Leuk Res. 2009;33(6):861\u20134.","journal-title":"Leuk Res"},{"key":"1103_CR7","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1016\/j.leukres.2011.08.007","volume":"36","author":"EM Orlandi","year":"2012","unstructured":"Orlandi EM, Rocca B, Pazzano AS, Ghio S. Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia. Leuk Res. 2012;36:e4\u20136.","journal-title":"Leuk Res"},{"key":"1103_CR8","doi-asserted-by":"crossref","unstructured":"Hennigs JK, Keller G, Baumann HJ, Honecker F, Kluge S, Bokemeyer C, et al. Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension? BMC Pulm Med. 2011; 11:30.","DOI":"10.1186\/1471-2466-11-30"},{"key":"1103_CR9","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/bmt.2008.415","volume":"43","author":"D Mattei","year":"2009","unstructured":"Mattei D, Feola M, Orzan F, Mordini N, Rapezzi D, Gallamini A. Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient. Bone Marrow Transplant. 2009;43:967\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"1103_CR10","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1164\/rccm.201001-0123OC","volume":"182","author":"HA Ghofrani","year":"2010","unstructured":"Ghofrani HA, Morrell NW, Hoeper MM, Olschewski H, Peacock AJ, Barst RJ, et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med. 2010;182:1171\u20137.","journal-title":"Am J Respir Crit Care Med"},{"key":"1103_CR11","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1183\/09031936.00054407","volume":"32","author":"MJ Overbeek","year":"2008","unstructured":"Overbeek MJ, van Nieuw Amerongen GP, Boonstra A, Smit EF, Vonk-Noordegraaf A. Possible role of imatinib in clinical pulmonary veno-occlusive disease. Eur Respir J. 2008;32:232\u20135.","journal-title":"Eur Respir J"},{"key":"1103_CR12","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1093\/eurheartj\/ehi891","volume":"27","author":"MH Williams","year":"2006","unstructured":"Williams MH, Handler CE, Akram R, Smith CJ, Das C, Smee J, Nair D, et al. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J. 2006;27:1485\u201394.","journal-title":"Eur Heart J"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-012-1103-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-012-1103-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-012-1103-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T05:01:46Z","timestamp":1559451706000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-012-1103-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,26]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["1103"],"URL":"https:\/\/doi.org\/10.1007\/s12185-012-1103-0","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,26]]}}}